Abstract
Most cell types can release vesicles. Cell-derived vesicles are increasingly recognized as an evolutionary wide-spread mechanism of intercellular communication. The paracrine and long range activity of vesicles and their regulated cargo-composition endows these vesicles with regulatory properties beyond that of the parental cell. The release and biogenesis of cell-derived vesicles is a dynamic and tightly controlled process. In the past years it has become clear that these vesicles exert a plethora of biological effects. This has sparked the intense interest in these vesicles in relation to (patho)physiological processes. This review focuses on the role of cell-derived vesicles in inflammation, with emphasis on the immune modulating capacity of immune cell-derived vesicles. The biological activity of different leukocyte-derived vesicles is compared, and potential explanations for the strong biological effects exhibited by vesicles are provided. The role of cell-derived vesicles in inflammatory processes is discussed by speculating how these vesicles can contribute to allergic inflammation.
Keywords: Exosome, microvesicle, microparticle, membrane vesicle, ectosome, allergy, immune regulation, immune cells
Current Pharmaceutical Design
Title:Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Volume: 18 Issue: 16
Author(s): Esther N.M. Nolte-‘t Hoen and Marca H.M. Wauben
Affiliation:
Keywords: Exosome, microvesicle, microparticle, membrane vesicle, ectosome, allergy, immune regulation, immune cells
Abstract: Most cell types can release vesicles. Cell-derived vesicles are increasingly recognized as an evolutionary wide-spread mechanism of intercellular communication. The paracrine and long range activity of vesicles and their regulated cargo-composition endows these vesicles with regulatory properties beyond that of the parental cell. The release and biogenesis of cell-derived vesicles is a dynamic and tightly controlled process. In the past years it has become clear that these vesicles exert a plethora of biological effects. This has sparked the intense interest in these vesicles in relation to (patho)physiological processes. This review focuses on the role of cell-derived vesicles in inflammation, with emphasis on the immune modulating capacity of immune cell-derived vesicles. The biological activity of different leukocyte-derived vesicles is compared, and potential explanations for the strong biological effects exhibited by vesicles are provided. The role of cell-derived vesicles in inflammatory processes is discussed by speculating how these vesicles can contribute to allergic inflammation.
Export Options
About this article
Cite this article as:
N.M. Nolte-‘t Hoen Esther and H.M. Wauben Marca, Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation, Current Pharmaceutical Design 2012; 18 (16) . https://dx.doi.org/10.2174/138161212800166013
DOI https://dx.doi.org/10.2174/138161212800166013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Sequential Bilateral Internal Jugular Vein Thrombosis: A Case Report and Review of this Rare Medical Entity
Vascular Disease Prevention (Discontinued) Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Role of the Non-Neuronal Human Cholinergic System in Lung Cancer and Mesothelioma: Possibility of New Therapeutic Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Survival Benefit of Adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the Different Time-points of Treatment of Ovarian Cancer: Review of Evidence
Current Pharmaceutical Design Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of lycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB
Current Neurovascular Research Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?
Current Medicinal Chemistry Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Molecular Targets and Targeted Therapies for Malignant Mesothelioma
Current Medicinal Chemistry Tumor Treating Fields – Behind and Beyond Inhibiting the Cancer Cell Cycle
CNS & Neurological Disorders - Drug Targets α7-Nicotinic Acetylcholine Receptors: An Old Actor for New Different Roles
Current Drug Targets Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA